Hyperprogressive disease: a distinct effect of immunotherapy?
作者信息
Popat Vinita, Gerber David E
机构信息
School of Medicine, UT Southwestern Medical Center, Dallas, Texas, USA.
Department of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas, USA.
出版信息
J Thorac Dis. 2019 Mar;11(Suppl 3):S262-S265. doi: 10.21037/jtd.2019.01.97.
Abstract
摘要
相似文献
1
Hyperprogressive disease: a distinct effect of immunotherapy?超进展性疾病：免疫疗法的一种独特效应？
J Thorac Dis. 2019 Mar;11(Suppl 3):S262-S265. doi: 10.21037/jtd.2019.01.97.
2
Nivolumab induced hyperprogressive disease in advanced esophageal squamous cell carcinoma.纳武单抗在晚期食管鳞状细胞癌中诱发了超进展性疾病。
Cancer Biol Ther. 2020 Dec 1;21(12):1097-1104. doi: 10.1080/15384047.2020.1834319. Epub 2020 Nov 5.
3
Hyperprogressive disease under anti-PD-1 rechallenge after initial response to anti-PD-1 treatment for non-small cell lung cancer: a case report.非小细胞肺癌患者在接受抗PD-1治疗初始缓解后再次接受抗PD-1治疗时出现的超进展性疾病：一例报告
Transl Lung Cancer Res. 2024 Mar 29;13(3):666-672. doi: 10.21037/tlcr-23-765. Epub 2024 Mar 27.
4
Is hyperprogressive disease a specific phenomenom of immunotherapy?超进展性疾病是免疫治疗的一种特定现象吗？
Explor Target Antitumor Ther. 2020;1(6):427-433. doi: 10.37349/etat.2020.00027. Epub 2020 Dec 28.
5
Hyperprogressive disease in non-small cell lung cancer after PD-1/PD-L1 inhibitors immunotherapy: underlying killer.抗 PD-1/PD-L1 抑制剂免疫治疗后非小细胞肺癌的超进展性疾病：潜在的“杀手”。
Front Immunol. 2023 May 22;14:1200875. doi: 10.3389/fimmu.2023.1200875. eCollection 2023.
6
Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don't) know.免疫检查点抑制剂治疗后出现超进展性疾病的机制：我们（不）知道什么。
J Exp Clin Cancer Res. 2020 Nov 9;39(1):236. doi: 10.1186/s13046-020-01721-9.
7
Histopathologic Evolution of Melanocytes Associated With Rapid Clinical Progression of Melanoma: Clinicopathologic Presentation of Hyperprogressive Disease in a Patient Treated With Immunotherapy.与黑色素瘤快速临床进展相关的黑色素细胞的组织病理学演变：免疫治疗患者中出现超进展性疾病的临床病理表现。
Am J Dermatopathol. 2022 Dec 1;44(12):921-924. doi: 10.1097/DAD.0000000000002315.
8
Hyperprogressive disease: A distinct pattern of progression to immune checkpoint inhibitors.Hyperprogressive disease：免疫检查点抑制剂治疗的一种独特进展模式。
Int J Cancer. 2021 Jul 15;149(2):277-286. doi: 10.1002/ijc.33429. Epub 2020 Dec 16.
9
Hyperprogressive Disease: Main Features and Key Controversies.Hyperprogressive Disease：主要特征和关键争议
Int J Mol Sci. 2021 Apr 3;22(7):3736. doi: 10.3390/ijms22073736.
10
Hyperprogressive disease: recognizing a novel pattern to improve patient management.Hyperprogressive disease：认识一种新的模式以改善患者管理。
Nat Rev Clin Oncol. 2018 Dec;15(12):748-762. doi: 10.1038/s41571-018-0111-2.
引用本文的文献
1
Hyperprogression of brain metastases following initiation of immune checkpoint inhibitors.免疫检查点抑制剂治疗开始后脑转移瘤的超进展
J Neurooncol. 2025 May;172(3):667-673. doi: 10.1007/s11060-025-04955-9. Epub 2025 Feb 7.
2
Incidence, Correlates, and Prognostic Significance of Mixed Response in Advanced Non-small Cell Lung Cancer.晚期非小细胞肺癌混合反应的发生率、相关性及其预后意义。
Oncologist. 2024 Apr 4;29(4):342-349. doi: 10.1093/oncolo/oyad335.
3
Pseudoprogression in advanced non-small cell lung cancer treated with combination chemoimmunotherapy: a case report.联合化疗免疫治疗后晚期非小细胞肺癌的假性进展：一例报告。
J Med Case Rep. 2022 Jul 25;16(1):289. doi: 10.1186/s13256-022-03485-6.
4
Hyperprogressive Disease After Combined Anti-PD-L1 and Anti-CTLA-4 Immunotherapy for MSI-H/dMMR Gastric Cancer: A Case Report.MSI-H/dMMR胃癌联合抗PD-L1和抗CTLA-4免疫治疗后的超进展性疾病：一例报告
Front Oncol. 2021 Sep 24;11:756365. doi: 10.3389/fonc.2021.756365. eCollection 2021.
5
The dark side of immunotherapy.免疫疗法的阴暗面。
Ann Transl Med. 2021 Jun;9(12):1041. doi: 10.21037/atm-20-4750.
6
TGF-β inhibition can overcome cancer primary resistance to PD-1 blockade: A mathematical model.TGF-β 抑制可以克服癌症对 PD-1 阻断的原发性耐药：一个数学模型。
PLoS One. 2021 Jun 1;16(6):e0252620. doi: 10.1371/journal.pone.0252620. eCollection 2021.
7
The Potential of T Cell Factor 1 in Sustaining CD8 T Lymphocyte-Directed Anti-Tumor Immunity.T细胞因子1在维持CD8 T淋巴细胞介导的抗肿瘤免疫中的潜力
Cancers (Basel). 2021 Jan 29;13(3):515. doi: 10.3390/cancers13030515.
8
PD-1 Blockade Aggravates Epstein-Barr Virus Post-Transplant Lymphoproliferative Disorder in Humanized Mice Resulting in Central Nervous System Involvement and CD4 T Cell Dysregulations.程序性死亡蛋白1（PD-1）阻断加重人源化小鼠移植后EB病毒淋巴增殖性疾病，导致中枢神经系统受累和CD4 T细胞失调。
Front Oncol. 2021 Jan 12;10:614876. doi: 10.3389/fonc.2020.614876. eCollection 2020.
9
Hyper-Progressive Disease: The Potential Role and Consequences of T-Regulatory Cells Foiling Anti-PD-1 Cancer Immunotherapy.超进展性疾病：调节性T细胞挫败抗PD-1癌症免疫疗法的潜在作用及后果
Cancers (Basel). 2020 Dec 26;13(1):48. doi: 10.3390/cancers13010048.
10
Immunotherapy Use in Patients With Lung Cancer and Comorbidities.免疫疗法在肺癌合并症患者中的应用。
Cancer J. 2020 Nov/Dec;26(6):525-536. doi: 10.1097/PPO.0000000000000484.
本文引用的文献
1
Immunogenomic Landscape Contributes to Hyperprogressive Disease after Anti-PD-1 Immunotherapy for Cancer.免疫基因组格局促成癌症抗PD-1免疫治疗后的超进展性疾病。
iScience. 2018 Nov 30;9:258-277. doi: 10.1016/j.isci.2018.10.021. Epub 2018 Oct 25.
2
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.抗 PD-1/PD-L1 抑制剂或单药化疗治疗的晚期非小细胞肺癌患者的超进展性疾病。
JAMA Oncol. 2018 Nov 1;4(11):1543-1552. doi: 10.1001/jamaoncol.2018.3676.
3
Hyperprogressive Disease in Anorectal Melanoma Treated by PD-1 Inhibitors.PD-1 抑制剂治疗肛门直肠黑色素瘤的超进展性疾病。
Front Immunol. 2018 Apr 19;9:797. doi: 10.3389/fimmu.2018.00797. eCollection 2018.
4
Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.肺免疫预后指数与晚期非小细胞肺癌患者免疫检查点抑制剂疗效的相关性。
JAMA Oncol. 2018 Mar 1;4(3):351-357. doi: 10.1001/jamaoncol.2017.4771.
5
Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria.PD-1 或 PDL-1 抑制剂治疗期间转移性 NSCLC 的反应模式：RECIST 1.1、irRECIST 和 iRECIST 标准的比较。
Eur J Cancer. 2018 Jan;88:38-47. doi: 10.1016/j.ejca.2017.10.017. Epub 2017 Nov 26.
6
Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.抗 PD-1/PD-L1 治疗复发性和/或转移性头颈部鳞状细胞癌患者中的超进展。
Ann Oncol. 2017 Jul 1;28(7):1605-1611. doi: 10.1093/annonc/mdx178.
7
Characterization of outcomes in patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors past RECIST version 1.1-defined disease progression in clinical trials.在临床试验中，对接受程序性细胞死亡蛋白1抑制剂治疗、疾病进展已超过RECIST 1.1版定义的转移性非小细胞肺癌患者的结局进行特征分析。
Semin Oncol. 2017 Feb;44(1):3-7. doi: 10.1053/j.seminoncol.2017.01.001. Epub 2017 Feb 10.
8
Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate.免疫治疗后的超进展者：与加速生长率相关的基因组改变分析。
Clin Cancer Res. 2017 Aug 1;23(15):4242-4250. doi: 10.1158/1078-0432.CCR-16-3133. Epub 2017 Mar 28.
9
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.iRECIST：免疫治疗试验中使用的疗效评估标准指南。
Lancet Oncol. 2017 Mar;18(3):e143-e152. doi: 10.1016/S1470-2045(17)30074-8. Epub 2017 Mar 2.
10
Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.抗 PD-1/PD-L1 治疗的癌症患者中出现的一种新的疾病进展模式：超进展性疾病
Clin Cancer Res. 2017 Apr 15;23(8):1920-1928. doi: 10.1158/1078-0432.CCR-16-1741. Epub 2016 Nov 8.
Zotero 插件